Abstract:Introduction Lung alveoli are essential for gas exchanges between air and blood. Alveoli can be destroyed as in emphysema, a disease in which an accumulation of senescent cells has been observed. No curative treatment is yet able to create new alveoli and regenerative treatments described in mice failed to be transferred successfully to patients with emphysema. This emphasizes the need to develop intermediate steps between mouse models and clinical trials for drug development in emphysema. Our aim was to develop 3D alveolar cell culture that could be used to screen senotherapeutic strategies, first organoids derived from alveolar epithelial and mesenchymal cell lines (H 441 and MRC5) and then patient-derived alveolospheres from epithelial cells. Methods H 441 and MRC5 were cocultured in a drop of Matrigel in 24 trans-well and 96-well plates. AT1 (HT1-56) and AT2 (HT2-280) markers were assessed by immunofluorescence. The variability of organoid sizes and shapes were assessed over time to determine the optimal number of cells (MRC5 and H 441 ). We first used 24 trans-well plates, and next miniaturized with 96-well plates. These seeding conditions were compared between day 8 and day 16 of culture. Several senescence inducers were tested to trigger reproducible senescence in H 441 : Doxorubicin (5 nM to 50 μM) and Etoposide (500 nM to 100 μM). Secondly, patient-derived alveolospheres were developed by isolating HT2-280 positive cells (AT2 cells) from human lung explants (Tata - Star protocol) and β-galactosidase was assessed to measure cell senescence. Results Culturing H 441 in Matrigel led to the formation of spheroidal 3D structures expressing both AT1 and AT2 markers. Co-culturing H 441 with MRC5 in Matrigel increased by 150% the organoid number compared to H 441 alone but did not affect their size. In all culture conditions the organoid size increased between day 8 and day 16 of culture. Increasing the amount of H 441 initially seeded with MRC5 increased the organoid number (230% between 625 and 1250 H 441 and 770% between 625 and 5K H 441 ) but does not influence their size. The best seeding condition for the 24 trans-well plate was 1250 H 441 with 50K MRC5 and for the 96-well plate is 250 H 441 with 2500 MRC5. The maximum non-toxic dose was 25 μM for etoposide and 5 μM for doxorubicin. Both treatments induced senescence in H 441 cells. When the alveolospheres have been passed, the percentage of β-galactosidase positive organoids was 40% at first passage and 52% at second passage. Conclusion We developed two senescent alveolar organoids assay that could be used to test senotherapeutic drugs.

Development of a senescent organoid assay from an epithelial cell line could be a way to identify seno-active drugs in human emphysema

Differentiated Fibroblastic Progenies of Human Embryonic Stem Cells for Toxicology Screening

Biochemical and transcriptomic evaluation of a 3D lung organoid platform for pre-clinical testing of active substances targeting senescence

Organoid-based expansion of patient-derived primary alveolar type 2 cells for establishment of alveolus epithelial Lung-Chip cultures

Development of human alveolar epithelial cell models to study distal lung biology and disease

Characterization an in vitro 3D alveolar model in COPD

Abstract P1-06-02: A Force-Sensitive Organoid Assay to Quantify Regenerative Potential of Single Primary Human Mammary Cells

An Optimized Protocol for the Generation of Alveolospheres from Wild-Type Mice

Modulating in vitro lung fibroblast activation via senolysis of senescent human alveolar epithelial cells

Generation of Complete Multi−Cell Type Lung Organoids From Human Embryonic and Patient‐Specific Induced Pluripotent Stem Cells for Infectious Disease Modeling and Therapeutics Validation

Ex Vivotissue Perturbations Coupled to Single Cell RNA-seq Reveal Multi-Lineage Cell Circuit Dynamics in Human Lung Fibrogenesis

A distal lung organoid model to study interstitial lung disease, viral infection and human lung development

A New Immortalized Human Alveolar Epithelial Cell Model to Study Lung Injury and Toxicity on a Breathing Lung-On-Chip System

Alveolar Organoids in Lung Disease Modeling

A novel in vitro tubular model to recapitulate features of distal airways: the bronchioid

Establishment of a human induced pluripotent stem cell derived alveolar organoid for toxicity assessment

Alveolar wars: The rise of in vitro models to understand human lung alveolar maintenance, regeneration, and disease

Using ex vivo bioengineered lungs to model pathologies and screening therapeutics: A proof‐of‐concept study

Optimization of Normal Human Bronchial Epithelial (NHBE) Cell 3D Cultures for in vitro Lung Model Studies

Engraftment and proliferation potential of embryonic lung tissue cells in irradiated mice with emphysema

In vitro model alveoli from photodegradable microsphere templates